New therapeutic approaches to modulate metabolic alterations in the cardiovascular system. In vivo studies

dc.contributor
Universitat de Barcelona. Facultat de Biologia
dc.contributor.author
Benítez Amaro, Aleyda
dc.date.accessioned
2023-01-25T10:20:18Z
dc.date.available
2023-01-25T10:20:18Z
dc.date.issued
2022-12-22
dc.identifier.uri
http://hdl.handle.net/10803/687492
dc.description
Programa de Doctorat en Biomedicina / Tesi realitzada a l'Institut d'Investigacions Biomèdiques de Barcelona (IIBB-CSIC)
ca
dc.description.abstract
[eng] BACKGROUND: Low-density lipoprotein receptor-related protein 1 (LRP1) plays a key role in fatty acid metabolism and glucose homeostasis. In the context of dyslipidemia, LRP1 is positively regulated in the heart. The LRP1 domain (CR9) and, in particular, the sequence Gly1127-Cys1140 (P3 peptide) is essential in the binding and internalization of aggregated LDL (agLDL). AgLDL internalization leads to intracellular cholesterol ester (CE) loading and foam cell formation in different cell types. The link between intracellular CE accumulation and insulin response is largely unknown. The first study aimed to evaluate the impact of cardiomyocyte Lrp1 deficiency on high-fat diet (HFD)-induced cardiac and metabolic alterations in a murine model and to explore the possible mechanisms involved. In the second and third studies, we aimed to evaluate whether immunization of rabbits with the P3 peptide reduces HFD-induced atherosclerosis and HFD-induced alterations in cardiac insulin response, respectively. METHODS STUDY I: We used TnT-iCre transgenic mice to generate an experimental mouse model with conditional Lrp1 deficiency in cardiomyocytes (TNT-iCre+-LRP1flox/flox). cm- Lrp1-/- (deficient) and cm-Lrp1+/+ (control) mice were fed with HFD and treated daily with Doxycycline Cyclate in drinking water for six weeks to inhibit Lrp1. After two weeks, mice were randomly assigned to untreated (PBS) or treated with natriuretic peptide receptor type A (NPRA) inhibitor until the end of the experiment. The indirect calorimetry study was performed at week 5 and glucose tolerance test at week 6. At the end of the experiment, target tissues were collected for molecular, lipidic, proteomic and immunohistochemical studies. METHODS STUDY II AND III: Rabbits immunized with irrelevant peptides (IrP) or P3 were randomized into HFD- or Chow-fed groups. Anti-P3 antibody (Abs) levels were determined by ELISA. Lipoprotein profile, circulating and tissue lipids, and vascular proinflammatory mediators were determined by standardized methods. Atherosclerosis was determined by confocal microscopy and noninvasive imaging studies. LRP1, Insulin receptor (InsR) and glucose transporter type 4 (GLUT4) levels were determined in rabbit heart membranes and total lysates. The interaction between InsR and LRP1 was analyzed by immunoprecipitation and confocal microscopy. Ex-vivo studies of cultured human macrophages (hMΦ), HL-1 cardiomyocytes, and vascular smooth muscle cells (VSMC) exposed to rabbit serum were conducted to explore the cell-specific effects of anti-P3 Abs. FINDINGS OF THE STUDIES: cm-Lrp1-/- mice have normal cardiac function combined with a favorable metabolic phenotype against HFD-induced glucose intolerance and obesity. Protection against glucose intolerance was associated with higher hepatic fatty acid oxidation (FAO), lower hepatic steatosis, and higher whole-body energy expenditure. Proteomic studies of the heart revealed reduced levels of cardiac pro-atrial natriuretic peptide (pro-ANP), which paralleled higher circulating levels and signaling of ANP. In the rabbit model, anti-P3 Abs reduced HFD-induced vascular CE accumulation and intracellular CE loading of hMΦ and VSMC as well as HFD-induced pro-inflammatory effects in these cells. Microscopy studies revealed that anti-P3 abs reduced the percentage of lipids, macrophages, and SMCs in the arterial intima, as well as the atherosclerotic extent and injured area in the aorta of hypercholesterolemic rabbits. Noninvasive imaging studies showed that aortic standardized mean uptake value (SUVmean) and carotid arterial resistance index (ARI) were upregulated by HFD to a much higher extent in control groups than in the P3-immunized group. In addition, anti-P3 abs not only decreases the amount of HFD-induced generation of lipid droplets (LDs) and glycogen drops into cardiomyocytes but also modify LD size, content and electrodensity. In addition, anti-P3 Abs restored the downregulatory effect of HFD on membrane InsR and GLUT4 levels as well as on LRP1/InsR interactions in rabbit hearts, and normalized the insulin signaling cascade and glucose uptake in HL-1 cells exposed to rabbit HFD serums.
ca
dc.format.extent
208 p.
ca
dc.language.iso
eng
ca
dc.publisher
Universitat de Barcelona
dc.rights.license
ADVERTIMENT. Tots els drets reservats. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs.
ca
dc.source
TDX (Tesis Doctorals en Xarxa)
dc.subject
Aterosclerosi
ca
dc.subject
Aterosclerosis
ca
dc.subject
Atherosclerosis
ca
dc.subject
Ecografia Doppler
ca
dc.subject
Ecografía Doppler
ca
dc.subject
Doppler ultrasonography
ca
dc.subject
Insulina
ca
dc.subject
Insulin
ca
dc.subject
Trastorns del metabolisme dels lípids
ca
dc.subject
Trastornos del metabolismo de los lípidos
ca
dc.subject
Lipid metabolism disorders
ca
dc.subject
Microscòpia electrònica
ca
dc.subject
Microscopia electrónica
ca
dc.subject
Electron microscopy
ca
dc.subject
Immunoteràpia
ca
dc.subject
Inmunoterapia
ca
dc.subject
Immunotheraphy
ca
dc.subject.other
Ciències Experimentals i Matemàtiques
ca
dc.title
New therapeutic approaches to modulate metabolic alterations in the cardiovascular system. In vivo studies
ca
dc.type
info:eu-repo/semantics/doctoralThesis
dc.type
info:eu-repo/semantics/publishedVersion
dc.subject.udc
577
ca
dc.contributor.director
Llorente Cortés, Concepción Vicenta
dc.contributor.tutor
Zorzano Olarte, Antonio
dc.embargo.terms
cap
ca
dc.rights.accessLevel
info:eu-repo/semantics/openAccess


Documents

ABA_PhD_THESIS.pdf

16.40Mb PDF

This item appears in the following Collection(s)